An observational study in HIV Infection, sponsored by Raincy Montfermeil Hospital Group. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by Raincy Montfermeil Hospital Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 278 studies in HIV Infections with a site in France — 19 open to participants now, 27 under way, 5 of them phase 3. HIV Infections · France.
Among the 278 studies in HIV Infections with a site in France, this one is the 8th largest by enrollment of the 59 observational ones that give a count, is one of 6 that started in 2021, is one of 59 observational ones, and was the 244th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →19 of the 278 studies in HIV Infections with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
ViiV Healthcare · Sites in France, United States, Argentina and 11 more countries
Ages 18+
Casper Rokx · Sites in France, Belgium, Germany and 7 more countries
Ages 18+ · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
278 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 72 · Phase 3 94 · Phase 4 18
First in 1999; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,347 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 186 across the 213 interventional studies, 200 across the 59 observational. Of the 232 that completed or were terminated, 70 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
111 of 278 have an industry lead sponsor. The 10 most frequent:
Raincy Montfermeil Hospital Group is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Raincy Montfermeil Hospital Group has 1 study filed under HIV Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in HIV Infections with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03296202University Hospital, BordeauxRisk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV | 2026-12 |
| NCT06441123University Hospital, MontpellierDevelopment of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein | 2027-02-10 |
| NCT07552038Nantes University HospitalDental Management of Patients With HIV in Pays de la Loire | 2027-05-30 |
| NCT07202546ViiV HealthcareA Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | 2027-10-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 278 studies in HIV Infections with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Insufficient screening and diagnostic delay play a significant role in sustaining the HIV epidemic by France.
Gender inequalities major factors reinforce social inequalities in order to of heterosexual men born abroad the most later diagnosed with HIV infection. Those gender differences are largely due to efficiency antenatal HIV screening, offered to women every pregnancy and widely accepted: a billed HIV serology in the context of pregnancy monitoring was found for 92% pregnant women benefiting from health insurance in 2015 the health of men is not taken into account in prenatal follow-up current French. The maternity hospital drains a population largely immigrant, often precarious The male prenatal consultation exists but it is not organized: it is possible to implement it, provided that the constraints exerted on men are taken into account.
the projet study the feasibility and the implementation processes place of prenatal consultation of future fathers
Insufficient screening and diagnostic delay play a significant role in sustaining the HIV epidemic by France. No significant decline is recorded in heterosexual, whether born in France or abroad. Gender inequalities major factors reinforce social inequalities in order to of heterosexual men born abroad the most later diagnosed with HIV infection. Those gender differences are largely due to efficiency antenatal HIV screening, offered to women every pregnancy and widely accepted: a billed HIV serology in the context of pregnancy monitoring was found for 92% pregnant women benefiting from health insurance in 2015. The arrival of a child could be an opportunity to screening for the future father as well. However, well that a consultation and a biological assessment intended for future fathers are provided for and fully reimbursed by the social security, the health of men is not taken into account in prenatal follow-up current French. The maternity hospital drains a population largely immigrant, often precarious. She puts in contact with the care of pregnant women who were sometimes distant, but not their companions: beyond the issue of reduction of the hidden HIV epidemic, increased needs for prevention and access to health appeared to us for the pilot phase of this project.
The population targeted by the data collection is the same as the population targeted by the intervention.
Are eligible for a prenatal consultation all men living in Ile de France including the companion is followed at the intercommunal hospital of Montreuil for a progressive pregnancy.
Women are also targeted by data collection. All women are eligible newly enrolled in the maternity ward of the Montreuil intercommunal hospital centre for a progressive pregnancy declaring a partner involved in the pregnancy and residing in Ile de France.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For future fathers
For future mothers
Exclusion Criteria:
evaluation of the proportion of fathers-to-be who fathers who accepted prenatal consultation among
Study the feasibility and processes of setting up the prenatal consultation of future fathers, through the different modalities proposed (in the maternity ward, elsewhere in the hospital, in the heart of city; during the day or in the evening; with or without an appointment) over a period of 26 months at the hospital intercommunal of Montreuil.
Time frame: 6 months
impact of male counselling on testing for HIV and other infections
Assessing the impact of male counselling on testing for HIV and other infections
Time frame: 6 months
impact of male consultation on vaccination coverage,
Evaluate the impact of male consultation on other interventions: on vaccination coverage, social security coverage and on the declaration of a attending physician.
Time frame: 6 months
Ran from Mar 2021 to primary completion in Jun 2022, 14 months.
Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 14 months is below that.
Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Raincy Montfermeil Hospital Group